Innovative therapies in clinical trials - 2021

Innowacyjne-terapie-www

Innovative therapies in clinical trials

 

Return to main conference page

We will talk about solutions that are just appearing on the horizon of therapeutic possibilities, but already have definitely tangible shapes. Our speakers will take us into the world of the future of medicine, which is happening today.

Block schedule
Speeches (9:00 - 11:00) Speakers
mRNA vaccines: from laboratory to clinical trials prof. Jacek Jemielity, Head of the Laboratory of Bioorganic Chemistry at the Center for New Technologies, Warsaw University
Going Into REVERSE - Assessing the Safety of Bacteriophage Treatment in the Management of Diabetic Foot Infections Clara Leandro, MSc, Technophage - Portugal
From bench to bedside – T regulatory cells in the clinic Prof. dr hab. Piotr Trzonkowski

mRNA vaccines: from laboratory to clinical trials

Jacek Jemielity
prof. Jacek Jemielity

Head of the Laboratory of Bioorganic Chemistry at the Center for New Technologies, Warsaw University

Biographical note: Prof. Jacek Jemielity is the head of the Laboratory of Bioorganic Chemistry at the Center for New Technologies (CENT) at Warsaw University. He received his PhD from the Department of Chemistry, University of Warsaw in 2002, and in the same year he started working as an assistant professor in the Division of Biophysics, IFD, Faculty of Physics, University of Warsaw. In 2020 he became a professor of chemistry. He is engaged in research on the synthesis, properties and applications of chemically modified nucleotides.

He develops methods to synthesize biologically important nucleotides, creates tools to modify nucleic acids useful in studies of genetic information expression and medical applications. He developed a method to obtain mRNA with properties necessary for therapeutic applications. His inventions are used in several clinical trials on cancer immunotherapy. He is the author of over 130 scientific publications in peer-reviewed scientific journals (including the most prestigious journals in the field such as Nucleic Acids Reserach, J. Am. Chem. Soc., Angewandte Chemie Int. Ed, RNA, Organic Lett., Chemical Science, Molecular Cell, Nature Structural & Molecular Biology, Nature Communications and others). His papers have been cited more than 2160 times. He has co-authored 6 patents protecting his inventions almost worldwide and several patent applications. One of these technologies involving mRNA modification is used in clinical trials for cancer vaccines by companies such as BioNTech, Sanofi, Roche, Pfizer. He is a scholarship holder of the Polityka weekly  (2008) and winner of the President of Poland's Economic Award in the "research + development" category (2017), he was nominated in the competition organized by the European Patent Office "European Inventor Award" 2018 in the category "Research". In his career collaboration with talented young people fascinated by scientific research has always been very important. He is the co-founder and president of ExploRNA Therapeutics, a UW spin off company focused on developing mRNA modification technologies and developing innovative mRNA-based therapies

Going Into REVERSE - Assessing the Safety of Bacteriophage Treatment in the Management of Diabetic Foot Infections

Clara Leandro
Clara Leandro MSc

Technophage - Portugal

Clara has a degree in Biology, MSc in Medical Parasitology and she is preparing her PhD dissertation in Biotechnology. In the past 16 years she has been actively working at Technophage SA, and as Head of the Infection therapeutic area she is the responsible for the bacteriophages team. Author of 32 scientific publications in peer-review journals, Clara also counts with several oral communications presented in international conferences. She collaborates with the University of Lisbon in teaching activities as invited lecturer.

Clara expertise includes the research of new antimicrobial products, namely bacteriophage-based therapies, and the development of experimental animal models for preclinical efficacy studies. Her knowledge in the field of bacteriophage biology motivated her inclusion in the Safety Review Committee of the Phase I clinical trial of Technophage's most advanced product directed at the treatment of diabetic foot infections.

From bench to bedside – T regulatory cells in the clinic

Piotr Trzonkowski
Prof. dr hab. Piotr Trzonkowski

Bio link